What does this research mean for the field?

Clonal hematopoiesis of indeterminate potential (CHIP) increases the 10-year cumulative incidence of heart failure to 20.3% vs 14.5% and ischemic cardiovascular disease (CVD) to 25.3% vs 18.5% among cancer patients receiving therapy. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

The study aims to evaluate the impact of clonal hematopoiesis on cardiovascular disease risk among cancer survivors after treatment.

January 10, 2026JAMA OncologyOpen Access

Clonal Hematopoiesis and Cardiovascular Disease Risk After Cancer Therapy in Patients With Solid Tumors

View Full Paper

Ask AI

Bookmark

Key result

CHIP linked to ~40% higher 10-year HF and ischemic CVD risk in cancer patients.

20.3% vs 14.5%
25.3% vs 18.5%

Why the study?

It is unknown whether clonal hematopoiesis of indeterminate potential amplifies therapy-related cardiovascular toxic effects in patients with cancer.

Does the presence of CHIP increase the risk of cardiovascular events in patients with solid tumors receiving cancer therapy?

Key Points

The study aims to evaluate the impact of clonal hematopoiesis on cardiovascular disease risk among cancer survivors after treatment.
Cohort study utilizing the BioVU biorepository and electronic health records.
Participants diagnosed with primary solid tumors received chemotherapy, radiotherapy, or immunotherapy.
Data analyzed from 2006 to 2025, focusing on cardiovascular events post-cancer therapy.
549 participants (6.9%) had clonal hematopoiesis.
Higher 10-year cumulative incidence of heart failure (20.3% vs 14.5%) and ischemic CVD (25.3% vs 18.5%) in those with CHIP.
CHIP associated with increased heart failure risk (subdistribution hazard ratio 1.26; P = .03).

Structured PICO

Does the presence of CHIP increase the risk of cardiovascular events in patients with solid tumors receiving cancer therapy?

Population

8,004 patients with a primary solid tumor diagnosis who received chemotherapy, radiotherapy, and/or immunotherapy, without prior hematologic malignant disease. Median age 61.9, 54.8% female.

Intervention

Presence of Clonal Hematopoiesis of Indeterminate Potential (CHIP) variants

Comparator

Absence of CHIP variants

Outcome

Time to first cardiovascular event, defined as heart failure, ischemic CVD, or arrhythmia following cancer treatmenthard clinical

The presence of CHIP is associated with an increased risk of cardiovascular disease, particularly heart failure, in patients with solid tumors undergoing cancer therapy.

Authors

DSDerek ShyrHarvard University YPYash PershadVanderbilt University Medical Center KZKun ZhaoBinzhou Medical University

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

CHIP may inform CV risk stratification in cancer survivors; extends observational CHIP-CVD links but leaves causal effects and practice change open.

Cite This Study

Shyr et al. (2026) studied this question. Clonal hematopoiesis of indeterminate potential (CHIP) increased the 10-year cumulative incidence of heart failure to 20.3% vs 14.5% and ischemic CVD to 25.3% vs 18.5% among cancer patients.

synapsesocial.com/papers/696321c091e05aa366cb7fdd https://doi.org/10.1001/jamaoncol.2025.5785

View Full Paper

Ask AI

Bookmark

Implication

CHIP may inform CV risk stratification in cancer survivors; extends observational CHIP-CVD links but leaves causal effects and practice change open.

Clonal Hematopoiesis and Cardiovascular Disease Risk After Cancer Therapy in Patients With Solid Tumors

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Clonal Hematopoiesis and Cardiovascular Disease Risk After Cancer Therapy in Patients With Solid Tumors

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider